Please use this identifier to cite or link to this item: https://doi.org/10.1111/cge.12392
DC FieldValue
dc.titleThe emerging era of pharmacogenomics: current successes, future potential, and challenges
dc.contributor.authorLee, JW
dc.contributor.authorAminkeng, F
dc.contributor.authorBhavsar, AP
dc.contributor.authorShaw, K
dc.contributor.authorCarleton, BC
dc.contributor.authorHayden, MR
dc.contributor.authorRoss, CJD
dc.date.accessioned2022-12-05T02:16:57Z
dc.date.available2022-12-05T02:16:57Z
dc.date.issued2014-07-01
dc.identifier.citationLee, JW, Aminkeng, F, Bhavsar, AP, Shaw, K, Carleton, BC, Hayden, MR, Ross, CJD (2014-07-01). The emerging era of pharmacogenomics: current successes, future potential, and challenges. CLINICAL GENETICS 86 (1) : 21-28. ScholarBank@NUS Repository. https://doi.org/10.1111/cge.12392
dc.identifier.issn0009-9163
dc.identifier.issn1399-0004
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/235301
dc.description.abstractThe vast range of genetic diversity contributes to a wonderful array of human traits and characteristics. Unfortunately, a consequence of this genetic diversity is large variability in drug response between people, meaning that no single medication is safe and effective in everyone. The debilitating and sometimes deadly consequences of adverse drug reactions (ADRs) are a major and unmet problem of modern medicine. Pharmacogenomics can uncover associations between genetic variation and drug safety and has the potential to predict ADRs in individual patients. Here we review pharmacogenomic successes leading to changes in clinical practice, as well as clinical areas probably to be impacted by pharmacogenomics in the near future. We also discuss some of the challenges, and potential solutions, that remain for the implementation of pharmacogenomic testing into clinical practice for the significant improvement of drug safety. © 2014 The Authors. Clinical Genetics published by JohnWiley & Sons A/S. Published by JohnWiley & Sons Ltd..
dc.language.isoen
dc.publisherWILEY
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectGenetics & Heredity
dc.subjectADRs
dc.subjectadverse drug reactions
dc.subjectanthracycline
dc.subjectcarbamazepine
dc.subjectcisplatin
dc.subjectcodeine
dc.subjectpharmacogenomics
dc.subjectwarfarin
dc.subjectANTHRACYCLINE-INDUCED CARDIOTOXICITY
dc.subjectIMPLEMENTATION CONSORTIUM GUIDELINES
dc.subjectWARFARIN DOSE REQUIREMENT
dc.subjectADVERSE DRUG-REACTIONS
dc.subjectGENETIC POLYMORPHISMS
dc.subjectHEARING-LOSS
dc.subjectCHILDREN
dc.subjectCODEINE
dc.subjectCYP2C9
dc.subjectCHILDHOOD
dc.typeReview
dc.date.updated2022-11-30T18:57:37Z
dc.contributor.departmentMEDICINE
dc.description.doi10.1111/cge.12392
dc.description.sourcetitleCLINICAL GENETICS
dc.description.volume86
dc.description.issue1
dc.description.page21-28
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
The emerging era of pharmacogenomics current successes, future potential, and challenges.pdf535.21 kBAdobe PDF

OPEN

PublishedView/Download

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.